modelEthinylestradiol
Extends from Pharmacolibrary.Drugs.ATC.L.L02AA03.
Information
| name: | Ethinylestradiol | |
| ATC code: | L02AA03 | route: | oral |
| compartments: | 1 | |
| dosage: | 30 | mg |
| volume of distribution: | 1.35 | L |
| clearance: | 15 | l/h |
| other parameters in model implementation | ||
Ethinylestradiol is a synthetic derivative of estradiol, used primarily as an oral contraceptive in combination with progestins. It is widely used for birth control and in hormone replacement therapy. Ethinylestradiol is an approved and commonly prescribed medication today.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult women after single oral dose.
References
Mohamed, MF, et al., & Othman, AA (2019). The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. Journal of clinical pharmacology 59(4) 510–516. DOI:10.1002/jcph.1350 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30500075
Kiriwat, O, & Fotherby, K (1983). Pharmacokinetics of oral contraceptive steroids after morning or evening administration. Contraception 27(2) 153–160. DOI:10.1016/0010-7824(83)90086-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/6851554
Ezuruike, U, et al., & Rowland Yeo, K (2018). Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach. Clinical pharmacology and therapeutics 104(6) 1229–1239. DOI:10.1002/cpt.1085 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29637542
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)